Seeing Is Believing
Currently, out of the existing stock ratings of Kevin Kedra - 4 which are a Buy (30.77%), 7 which are a Hold (53.85%), 2 which are a Sell (15.38%)
Analyst Kevin Kedra works at GABELLI and is covering the Healthcare sector with 25 price targets and ratings displayed on 4 stocks.
Kevin Kedra's average stock forecast success ratio is 66.67% with an average time for price targets to be met of 430.67 days.
Most recent stock forecast was given on LXRX, Lexicon Pharmaceuticals at 15-Jan-2021.
Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
8
$6.84 (589.66%)
3 months 21 days ago
4/16 (25%)
$8.71 (111.98%)
36
Buy
10
$8.84 (762.07%)
10
11 months 18 days ago
0/2 (0%)
$7.19 (261.81%)
Hold
6
$4.84 (417.24%)
3
2 years 6 months 10 days ago
2/5 (40%)
$5.39 (60.47%)
43
Hold
2
$0.84 (72.41%)
38
2 years 7 months 23 days ago
2/9 (22.22%)
$12.67 (82.00%)
409
Hold
7
$5.84 (503.45%)
2 years 7 months 23 days ago
3/3 (100%)
$1.33 (13.05%)
55
What Year was the first public recommendation made by Kevin Kedra?